What happens when Levels of IgG4 (tolerant antibody) Falls?

May 25, 2024 | COVID-19, Research, Treatment

Exploring the impact of declining IgG4 levels post-vaccination on immunity and potential risks.

  • Dr. Philip McMillan discusses the significance of IgG4 levels in immunity post-vaccination. • 0:03

  • Antibody levels post-infection typically average around 300 nanog per mil. • 1:58

  • Concerns raised about significant rise in IgG4 levels post-vaccination. • 2:26

  • IgG4, an unusual pattern in mRNA vaccination, poses potential risks to immune response. • 4:06

Impact of IgG4 levels post-vaccination on immune response and viral replication.

  • IgG4 triggers immune system response, while IgG4 dampens it down. • 4:30

  • Significant increase in IgG4 levels post mRNA vaccination. • 6:00

  • Unexpected tolerance development towards Spike protein post-vaccination. • 6:32

  • IgG4 interferes with virus cell entry but not replication. • 7:05

  • High levels of viral dissemination observed in vaccinated cohorts. • 7:32

  • Shift towards IgG4 antibodies post mRNA vaccination. • 7:48

  • Increased IgG4 levels post-vaccination regardless of prior infection. • 8:25

Implications of low IgG4 levels in viral infections and vaccine response.

  • Low levels of IgG4 in viral infections may lead to viral dissemination. • 9:27

  • High levels of IgG4 may interfere with viral replication. • 9:47

  • Tolerant antibodies suppressing the immune system raises concerns when they fall. • 10:14

  • Risk-benefit analysis needed for vaccine interventions. • 10:41

  • Importance of understanding disease presentation and vaccine uptake. • 11:11

  • Data on antibody levels can provide insights into immunity trajectories. • 11:48

  • Minimum IgG4 levels in normal infection compared to observed levels. • 12:05

Concerns regarding declining IgG4 levels and potential hyperimmune response.

  • Antibody levels above 800 nanograms per mill considered protective. • 12:47

  • Up to 93% in age group under 65 and 98% in over 65s had protective antibody levels. • 12:54

  • Low vaccine booster uptake despite high antibody levels in certain age groups. • 13:33

  • 30-40% of age group 16-24 have antibody levels between 179 to 800 nanograms per mill. • 14:04

  • Concerns raised about majority having antibody levels above 6,000 in older age groups. • 15:30

  • Shift from IgG4 to cellular response when levels fall may lead to hyperimmune response. • 16:52

  • Potential risk of hyperimmune response due to lack of IgG4 and viral dissemination. • 17:00

Potential consequences of declining IgG4 levels and the uncertainty surrounding further antibody boosting.

  • Concerns about immune response targeting various organs beyond the lung. • 17:43

  • Uncertainty on the effectiveness of further antibody boostin. • 18:17

  • Lack of clarity on managing potential inflammatory response. • 19:01

  • Suggestion to consider alternative immune-suppressing treatment. • 19:25

  • Critique of leadership’s handling of public health challenge. • 19:47

  • Call for scientific preparation and readiness for potential adverse outcome. • 20:03

  • Encouragement to stay informed and proactiv. • 20:12